Comparative Pharmacology
Head-to-head clinical analysis: FEXINIDAZOLE versus IMPAVIDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXINIDAZOLE versus IMPAVIDO.
FEXINIDAZOLE vs IMPAVIDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexinidazole is a nitroimidazole derivative that enters the parasite and inhibits DNA synthesis by forming reactive metabolites, leading to cell death. It is active against Trypanosoma brucei gambiense.
Miltefosine, the active ingredient in IMPAVIDO, is an alkylphosphocholine with antileishmanial activity. It interacts with cell membrane phospholipids, inhibits cytochrome c oxidase, and induces apoptosis-like cell death in Leishmania parasites. It also modulates host immune responses.
500 mg orally twice daily for 10 days for trichomoniasis; 2 g orally single dose for giardiasis.
60 mg/kg body weight per day (2.5 mg/kg per hour) by intravenous infusion over 6 hours, up to a maximum of 150 mg/day, for 21 days.
None Documented
None Documented
Approximately 8-12 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 16-21 days in adults; may be longer in severe hepatic impairment.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal.
Primarily renal (over 90% as unchanged drug); fecal excretion is minimal (<5%).
Category C
Category C
Antiprotozoal
Antiprotozoal